Dicerna Pharmaceuticals (DRNA) Analysts See $-0.61 EPS; Katy Industries (KT) Sentiment Is 0.89

July 20, 2017 - By Kurt Siggers

KT Corporation is a telecommunications service provider. The company has market cap of $7.75 billion. The Company’s divisions include the Customer/Marketing Group, the Finance Business Group and the Others Group. It has a 11.72 P/E ratio. The Customer/Marketing Group segment is engaged in providing various telecommunication services to individual/home/corporate clients and the convergence business.

Analysts expect Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) to report $-0.61 EPS on August, 3.They anticipate $0.14 EPS change or 18.67% from last quarter’s $-0.75 EPS. After having $-0.68 EPS previously, Dicerna Pharmaceuticals Inc’s analysts see -10.29% EPS growth. The stock decreased 1.46% or $0.05 on July 19, reaching $3.37. About shares traded. Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) has declined 5.22% since July 20, 2016 and is downtrending. It has underperformed by 21.92% the S&P500.

Silchester International Investors Llp holds 19.47% of its portfolio in KT Corp (ADR) for 25.81 million shares. Mittleman Brothers Llc owns 1.53 million shares or 10.69% of their US portfolio. Moreover, Somerset Capital Management Llp has 6% invested in the company for 1.36 million shares. The California-based Sensato Investors Llc has invested 4.72% in the stock. Kiltearn Partners Llp, a United Kingdom-based fund reported 8.26 million shares.

The stock increased 0.35% or $0.06 during the last trading session, reaching $17.29. About shares traded. KT Corp (ADR) (KT) has risen 15.78% since July 20, 2016 and is uptrending. It has underperformed by 0.92% the S&P500.

Among 5 analysts covering Dicerna Pharmaceuticals (NASDAQ:DRNA), 3 have Buy rating, 0 Sell and 2 Hold. Therefore 60% are positive. Dicerna Pharmaceuticals had 13 analyst reports since August 7, 2015 according to SRatingsIntel. As per Tuesday, May 10, the company rating was maintained by Stifel Nicolaus. Cowen & Co maintained Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) on Tuesday, July 18 with “Buy” rating. Stifel Nicolaus maintained it with “Buy” rating and $13 target in Thursday, June 30 report. Chardan Capital Markets maintained Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) rating on Monday, August 15. Chardan Capital Markets has “Neutral” rating and $3.50 target. Leerink Swann reinitiated the stock with “Mkt Perform” rating in Tuesday, January 31 report. The firm earned “Buy” rating on Monday, December 12 by H.C. Wainwright. Stifel Nicolaus maintained the shares of DRNA in report on Monday, August 10 with “Buy” rating. The company was initiated on Tuesday, September 8 by Cowen & Co. The rating was maintained by Stifel Nicolaus on Wednesday, November 11 with “Buy”. On Thursday, June 30 the stock rating was maintained by Chardan Capital Markets with “Neutral”.

Investors sentiment increased to 1.09 in Q4 2016. Its up 0.53, from 0.56 in 2016Q3. It increased, as 10 investors sold Dicerna Pharmaceuticals Inc shares while 13 reduced holdings. 10 funds opened positions while 15 raised stakes. 10.74 million shares or 7.45% less from 11.61 million shares in 2016Q3 were reported. Bourgeon Capital Lc stated it has 0.08% of its portfolio in Dicerna Pharmaceuticals Inc (NASDAQ:DRNA). The New York-based Tower Research Ltd (Trc) has invested 0% in Dicerna Pharmaceuticals Inc (NASDAQ:DRNA). 300 are owned by Prelude Mngmt Limited Com. Blackrock Advsr Lc has 2,670 shares for 0% of their portfolio. Fmr Ltd Liability Company reported 0% of its portfolio in Dicerna Pharmaceuticals Inc (NASDAQ:DRNA). Qs reported 0% of its portfolio in Dicerna Pharmaceuticals Inc (NASDAQ:DRNA). Renaissance Techs Ltd Liability Corporation has 408,682 shares for 0% of their portfolio. Bnp Paribas Arbitrage holds 0% in Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) or 32 shares. 3,479 were accumulated by Barclays Pcl. California Pub Employees Retirement has 0% invested in Dicerna Pharmaceuticals Inc (NASDAQ:DRNA). Deutsche Bankshares Ag holds 0% of its portfolio in Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) for 41,050 shares. Comml Bank Of New York Mellon stated it has 28,769 shares. Northern Trust Corp owns 32,851 shares. Blackrock Fund Advisors reported 44,002 shares or 0% of all its holdings. Federated Inc Pa stated it has 1,541 shares or 0% of all its holdings.

Dicerna Pharmaceuticals, Inc. is a ribonucleic acid interference biopharmaceutical company. The company has market cap of $70.28 million. The Firm operates in the segment of discovery, research and development of treatments based on its RNA interference (RNAi) technology platform. It currently has negative earnings. The Firm is focused on the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined.